| Expression of growth hormone, growth hormone releasing hormone, and somatostatin genes is unperturbed in the streptozotocin-induced diabetic rat. | |
| | |
MedLine Citation:
|
PMID: 1686555 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The effects of streptozotocin diabetes on the level of growth hormone, growth hormone releasing hormone, and somatostatin mRNA was measured in control rats, in diabetic rats maintained on insulin, and in diabetic rats in which insulin had been withheld for 3 days. Total cytoplasmic RNA samples were prepared from the pituitary and hypothalamic tissues of each animal and analyzed by dot blot or Northern blot hybridization. No significant difference was observed between control and insulin-treated groups with regard to body weight or plasma glucose concentration. The insulin withdrawal group had significantly higher plasma glucose concentrations and lower body weights, confirming diabetic status. There was no significant difference in the level of growth hormone, growth hormone releasing hormone, and somatostatin mRNA among any of the three groups however. We conclude that alterations in the regulation of circulating growth hormone in the streptozotocin-induced diabetic rat, removed from insulin treatment for 3 days, did not occur at the transcriptional or RNA processing level. This conclusion extends to hypothalamic growth hormone releasing hormone, and somatostatin gene expression as well. Regulatory changes in growth hormone level previously noted during insulin withdrawal in the streptozotocin-induced diabetic rat could be the result of post-transcriptional processes operating at the level of hormone synthesis or release. |
| | |
Authors:
|
J G Lee; R C Bird; E H Oliver; J L Sartin |
Related Documents
:
|
22913735 - Linagliptin: a review of its use in the management of type 2 diabetes mellitus. 1884885 - In vivo metabolic action of insulin-like growth factor i in adult rats. 2324285 - Impact of the bactec nr system in detecting candida fungemia. 22428185 - Ranibizumab and diabetic macular oedema: after laser therapy. 18280655 - Reduced cyp2d6 activity is a negative risk factor for methamphetamine dependence. 21103235 - Non-alcoholic steatohepatitis in myotonic dystrophy: dmpk gene mutation, insulin resist... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S. |
Journal Detail:
|
Title: Biochemistry and cell biology = Biochimie et biologie cellulaire Volume: 69 ISSN: 0829-8211 ISO Abbreviation: Biochem. Cell Biol. Publication Date: 1991 Jul |
Date Detail:
|
Created Date: 1992-04-06 Completed Date: 1992-04-06 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8606068 Medline TA: Biochem Cell Biol Country: CANADA |
Other Details:
|
Languages: eng Pagination: 428-32 Citation Subset: IM |
Affiliation:
|
Department of Pathobiology, College of Veterinary Medicine, Auburn University, AL 36849. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Blood Glucose / analysis Blotting, Northern Body Weight Diabetes Mellitus, Experimental / drug therapy, genetics* Gene Expression Regulation / drug effects, genetics Growth Hormone / genetics* Growth Hormone-Releasing Hormone / genetics* Hypothalamus / drug effects, metabolism Insulin / pharmacology Male RNA, Messenger / analysis, genetics Rats Rats, Inbred Strains Somatostatin / genetics* Streptozocin / pharmacology Transcription, Genetic / drug effects, genetics* |
| Chemical | |
Reg. No./Substance:
|
0/Blood Glucose; 0/RNA, Messenger; 11061-68-0/Insulin; 18883-66-4/Streptozocin; 51110-01-1/Somatostatin; 9002-72-6/Growth Hormone; 9034-39-3/Growth Hormone-Releasing Hormone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Different susceptibility of elastase inhibitors to inactivation by proteinases from Staphylococcus a...
Next Document: Synthesis and beta-adrenergic antagonist activity of novel (3-cyanodihydropyridyl)propanolamines.